Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. ACADIA Pharmaceuticals's current 1-Year Share Buyback Ratio was -2.10%.
ACAD's 1-Year Share Buyback Ratio is ranked better than 75.29% of 1113
companies
in the Biotechnology industry
Industry Median: -14.5
vs ACAD: -2.10
ACADIA Pharmaceuticals (NAS:ACAD) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
ACADIA Pharmaceuticals 1-Year Share Buyback Ratio Related Terms
ACAD vs LEGN, TNGX, CAI: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -2.10 mean?
ACADIA Pharmaceuticals (ACAD) has a 1-Year Share Buyback Ratio of -2.10 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for ACADIA Pharmaceuticals and its competitors. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #275 out of 1113 companies in the Biotechnology industry, placing it in the top 24.7%.
Is ACADIA Pharmaceuticals' 1-Year Share Buyback Ratio too high?
ACADIA Pharmaceuticals' current 1-Year Share Buyback Ratio is -2.10. Based on the distribution chart, ACADIA Pharmaceuticals ranks #275 out of 1113 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' 1-Year Share Buyback Ratio compare to LEGN and TNGX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #275 out of 1113 companies for 1-Year Share Buyback Ratio. This places ACADIA Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current 1-Year Share Buyback Ratio is -2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.05, compared to a current price of $29.33 — trading 17.1% above its estimated fair value. The current 1-Year Share Buyback Ratio is -2.10. ACADIA Pharmaceuticals' overall GF Score™ is 78/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For ACADIA Pharmaceuticals (ACAD), the current 1-Year Share Buyback Ratio is -2.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of $29.33 is trading 17.1% above its estimated GF Value™ of $25.05.
GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ACAD:
1-Year Share Buyback Ratio: -2.10
GF Value™: $25.05 vs. price of $29.33 (17.1% above fair value)
No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
78GF Score
Get the complete analysis for ACAD
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACAD has been successfully added to your 
